Prognostic and clinicopathological utility of PD-L2 expression in patients with digestive system cancers: A meta-analysis,International Immunopharmacology

当前位置： X-MOL 学术 › Int. Immunopharmacol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Prognostic and clinicopathological utility of PD-L2 expression in patients with digestive system cancers: A meta-analysis
International Immunopharmacology ( IF 4.8 ) Pub Date : 2020-09-10 , DOI: 10.1016/j.intimp.2020.106946
Xiaochun Lin , Kunpeng Lin , Chunxuan Lin , Jiakang Wang , Yunqiang Tang

Objective

Programmed death ligand-2 (PD-L2) has been detected in various cancers. However, its prognostic value in digestive system cancers (DSCs) remains unclear. Accordingly, this meta-analysis investigated the prognostic and clinicopathological utility of PD-L2 in patients with DSCs.

Methods

We systematically searched PubMed, EMBASE, Web of Science, ClinicalTrials.gov., Scopus, and Cochrane Library databases for eligible studies up to April 30, 2020. The hazard ratio (HR), odds ratio (OR), and corresponding 95% confidence interval (CI) of the outcomes were calculated.

Results

Twenty two studies with 4886 patients were included in this meta-analysis. The pooled results showed that PD-L2 overexpression was significantly associated with poor overall survival (OS) (HR 1.470, 95% CI: 1.252–1.728, p < 0.001) and worse disease-free survival (DFS) (HR1.598, 95% CI: 1.398–1.826, p < 0.001). Subgroup analysis revealed that elevated PD-L2 was a significant prognostic indicator of worse OS in hepatocellular carcinoma (HR 1.703, 95% CI: 1.456–1.991, p < 0.001) and colorectal cancer (HR 3.811, 95% CI: 1.718–8.454, p = 0.001). Concerning clinicopathologic factors, PD-L2 overexpression was associated with lymphatic metastasis (OR 1.394., 95% CI: 1.101–1.764, p = 0.006), tumor metastasis (OR 1.599, 95% CI: 1.072–2.383, p = 0.021), and the histopathological stage (OR 0.704, 95% CI: 0.566–0.875, p = 0.002).

Conclusion

PD-L2 overexpression in DSCs after surgery might predict a poor prognosis, especially in hepatocellular carcinoma and colorectal cancer. Larger patient cohorts are needed to validate its prognostic role.

中文翻译：

PD-L2在消化系统癌症患者中的表达对预后和临床病理的实用性：一项荟萃分析

目的

在多种癌症中已检测到程序性死亡配体2（PD-L2）。但是，其在消化系统癌症（DSC）中的预后价值仍不清楚。因此，这项荟萃分析研究了PD-L2在DSC患者中的预后和临床病理学用途。

方法

我们系统搜索了PubMed，EMBASE，Web of Science，ClinicalTrials.gov。，Scopus和Cochrane图书馆数据库，以进行截至2020年4月30日的合格研究。危险比（HR），优势比（OR）和相应的95％置信度计算结果的间隔（CI）。

结果

该荟萃分析包括22项针对4886例患者的研究。汇总结果显示，PD-L2过表达与总体生存率（OS）差（HR 1.470，95％CI：1.252–1.728，p <0.001）和无病生存期差（DFS）（HR1.598，95）显着相关。％CI：1.398–1.826，p <0.001）。亚组分析显示，PD-L2升高是肝细胞癌（HR 1.703，95％CI：1.456–1.991，p <0.001）和结直肠癌（HR 3.811，95％CI：1.718–8.454）的OS恶化的重要预后指标。 p = 0.001）。关于临床病理因素，PD-L2过表达与淋巴结转移有关（OR 1.394。，95％CI：1.101–1.764，p = 0.006），肿瘤转移（OR 1.599，95％CI：1.072–2.383，p = 0.021），组织病理学阶段（OR 0.704，95％CI：0.566–0.875，p = 0.002）。